Patent intelligence · US
US 11261151
Methods for making and using endoxifen
Methods for making and using endoxifen
Patent details — US 11261151
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 1, 2022
- Expiration
- Feb 24, 2042
- Applicant
- ATOSSA THERAPEUTICS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61K9/0053, A61P
Quick answer
US 11261151 (Methods for making and using endoxifen) is held by ATOSSA THERAPEUTICS, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ATOSSA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61K9/0053, A61P, A61P35/00
More from ATOSSA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12281056
Methods for making and using endoxifen
granted -
US 12275684
Methods for making and using endoxifen
granted -
US 12201591
Sustained release compositions of endoxifen
granted -
US 12071391
Methods for making and using endoxifen
granted -
US 11680036
Methods for making and using endoxifen
granted -
US 11572334
Methods for making and using endoxifen
granted -
US 6894026
Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
expired
Related coverage
FDA Approves Lumasiran for PH1: What BD and Investors Should Know
This rewrite clarifies that FDA-approved Givlaari (givosiran) is indicated for adults with acute hepatic porphyria, while OXLUMO (lumasiran) is approved for PH1. The article should frame the catalyst as a regulatory and portfolio update, not a new AHP label for lumasiran.
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
The FDA has approved FoundationOne CDx as a companion diagnostic for inavolisib (Itovebi) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. This approval expands the targeted therapy landscape and underscores the importance of genomic testing in patient selection.
Frequently asked questions
What is US patent 11261151?
US 11261151 (Methods for making and using endoxifen) is held by ATOSSA THERAPEUTICS, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11261151?
ATOSSA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11261151 expire?
Our index shows an expiration date of Feb 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.